新型冠状病毒肺炎中的严重血小板减少症：登革热流行地区的一个难题
Severe Thrombocytopenia in COVID-19: A Conundrum in Dengue-endemic Areas.
作者信息
Adarsh M B, Abraham Anitha, Kavitha P, Nandakumar Meera M, Vaman Raman S
机构信息
Department of General Medicine, Government Medical College, Kasaragod, Kerala, India.
Department of Community Medicine, Government Medical College, Kasaragod, Kerala, India.
出版信息
Indian J Crit Care Med. 2021 Apr;25(4):465-466. doi: 10.5005/jp-journals-10071-23778.
UNLABELLED
Thrombocytopenia in coronavirus disease-2019 (COVID-19) can be attributed to multiple factors. Most often it is disease related. It is usually mild and if severe often associated with severe COVID-19 disease. It can also be due to drugs (Remdesivir, Tocilizumab) or coinfection with other viruses. Here we report two cases of severe thrombocytopenia in COVID-19 due to dengue coinfection. Most often the thrombocytopenia in dengue is self-resolving, and a careful "wait and watch" should suffice unlike COVID-19, where steroids can help if the cytopenia is due to cytokine storm or immune-mediated effects.
HOW TO CITE THIS ARTICLE
Adarsh MB, Abraham A, Kavitha P, Nandakumar MM, Vaman RS. Severe Thrombocytopenia in COVID-19: A Conundrum in Dengue-endemic Areas. Indian J Crit Care Med 2021;25(4):465-466.
未标注
2019冠状病毒病（COVID-19）中的血小板减少症可归因于多种因素。最常见的是与疾病相关。通常症状较轻，若严重则常与重症COVID-19疾病相关。它也可能由药物（瑞德西韦、托珠单抗）或与其他病毒合并感染引起。在此，我们报告两例因登革热合并感染导致COVID-19出现严重血小板减少症的病例。登革热中的血小板减少症大多可自行缓解，与COVID-19不同，若血细胞减少是由细胞因子风暴或免疫介导效应引起，在COVID-19中使用类固醇可能会有帮助，对此仔细的“观察等待”通常就足够了。
如何引用本文
Adarsh MB, Abraham A, Kavitha P, Nandakumar MM, Vaman RS. COVID-19中的严重血小板减少症：登革热流行地区的一个难题。《印度重症监护医学杂志》2021年；25(4):465 - 466。
Zotero 插件